Bezos-Backed Grail Plans Commercial Push on Multi-Cancer Test

Grail, a privately-held company backed by Jeff Bezos and Bill Gates, will push forward on plans to commercialize a simple blood test meant to find several different kinds of deadly cancers in patients early.

One study, known as the “Circulating Cell-free Genome Atlas,” or CCGA, showed that Grail’s liquid biopsy test could find 12 different types of cancers, including colon, breast and lung, at an early stage with a rate of false positives of 1% or less. That’s a key measure of whether patients could be told they have cancer when they don’t.